ceftiofur and Acute-Disease

To determine whether ceftiofur sodium would be useful for treatment of acute interdigital phlegmon (foot rot) in cattle.. Randomized controlled trial.. 308 cross-bred yearling steers with clinical signs of acute interdigital phlegmon (i.e., lameness with interdigital swelling, interdigital lesions, or both).. Steers were randomly assigned to 1 of 3 treatment groups: ceftiofur at a dosage of 0.1 mg/kg (0.045 mg/lb) of body weight, IM, every 24 hours; ceftiofur at a dosage of 1.0 mg/kg (0.45 mg/lb), IM, every 24 hours, and oxytetracycline at a dosage of 6.6 mg/kg (3 mg/lb), IM, every 24 hours. All animals were treated for 3 days; treatment was considered successful if animals were no longer lame on day 4. Biopsy specimens were collected prior to treatment from 5 animals in each group and submitted for anaerobic bacterial culture and histologic examination.. Success rates for the high-dosage ceftiofur (94/129; 73%) and oxytetracycline (87/128; 68%) groups were significantly higher than that for the low-dosage ceftiofur group (5/50; 10%), but there were no significant differences between the high-dosage ceftiofur and oxytetracycline groups. Anaerobic bacteria most frequently isolated from biopsy specimens were Porphyromonas levii and Provetella intermedia.. Use of ceftiofur at a dosage of 1.0 mg/kg for treatment of cattle with acute interdigital phlegmon was as effective as use of oxytetracycline at a dosage of 6.6 mg/kg. However, ceftiofur has a negligible withdrawal time and, therefore, may be a better choice for treatment of near-market weight animals.

Topics: Acute Disease; Animals; Anti-Bacterial Agents; Bacteroidaceae Infections; Biopsy; Cattle; Cattle Diseases; Cephalosporins; Dose-Response Relationship, Drug; Foot; Foot Rot; Lameness, Animal; Oxytetracycline; Porphyromonas; Time Factors

The purpose of the present clinical studies was to determine the clinical efficacy of a combined parenteral and oral treatment with Bisolvon in combination with antibiotics in bovines suffering from acute respiratory disease. To this end four trials were conducted in respiratory diseased bovines; a total of 619 animals were evaluated. The animals were randomly assigned to one of two treatment groups within each study and were treated either with enrofloxacin, cefquinome, ceftiofur or florfenicol. The Bisolvon group was additionally treated with Bisolvon over 5 consecutive days. Daily clinical examinations were carried out over a period of 6 days. The clinical respiratory score, the primary parameter, representing a summation of the scoring points for the parameters respiratory rate, nasal discharge, spontaneous coughing, lung sounds and grade of dyspnoea and the clinical index score, which additionally included the general parameters fever, demeanour and feed intake, were significantly lower in the Bisolvon groups compared to the controls at all examinations after initiation of therapy in all trials with the exception of day 2 in one study. Lower values correspond to a less severe clinical condition. This consistent result as well as the evaluation of the single parameters are indicative of an acceleration of the recovery of the animals additionally treated with Bisolvon.

Topics: Acute Disease; Administration, Oral; Animals; Anti-Infective Agents; Bromhexine; Cattle; Cattle Diseases; Cephalosporins; Drug Therapy, Combination; Enrofloxacin; Fluoroquinolones; Injections; Quinolones; Respiratory Tract Infections; Thiamphenicol

This report was delineated to study the clinical, bacteriological and therapeutic aspects concerned with acute coliform mastitis in buffaloes. Bacteriological examination of 80 quarter milk samples obtained aseptically from 56 buffaloes with acute mastitis revealed that coliform bacteria was the most common pathogen (45 cases) followed by Staphylococcus aureus (seven cases) then Streptococcus uberis (three cases), and Streptococcus agalactiae (one case). Clinically, hotness, swelling and painful reaction with serous excretion containing clots was recorded in buffaloes with coliform mastitis. The efficacy of ceftiofur was evaluated in the treatment of buffaloes with acute coliform mastitis. Parenteral ceftiofur neither improved clinical signs nor returned milk to pre-infection production level, whereas intramammary ceftiofur and combination of intramammary with parenteral ceftiofur improved the clinical signs in 10/15 and 12/15 buffaloes, respectively. On quarter level, 3/17, 12/17 and 15/21 quarters recovered in groups received parenteral, intramammary and combination therapy, respectively. This study demonstrates that systemic ceftofur is not effective in the treatment of clinical coliform mastitis in buffaloes.

Topics: Acute Disease; Animals; Anti-Bacterial Agents; Buffaloes; Cephalosporins; Drug Administration Routes; Drug Therapy, Combination; Enterobacteriaceae; Enterobacteriaceae Infections; Female; Infusions, Parenteral; Mastitis; Treatment Failure; Treatment Outcome